Skip to main content
. 2010 Jun 8;89(11):1133–1140. doi: 10.1007/s00277-010-0992-3

Fig. 1.

Fig. 1

Time to progression (panel a), progression-free survival (panel b), and overall survival (panel c) of patients treated for their relapsed and/or refractory multiple myeloma with PLD + bortezomib is plotted based on the presence of either the A/G or G/G SNP at R723Q in MRP 1 using the Kaplan–Meier method